Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
McKinsey
Harvard Business School
Johnson and Johnson

Last Updated: May 26, 2022

Hospira Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Hospira

Drugs and US Patents for Hospira

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% heparin sodium INJECTABLE;INJECTION 018911-007 Jan 30, 1985 DISCN No No See Plans and Pricing See Plans and Pricing
Hospira MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 020488-002 Jul 11, 1995 RX Yes Yes See Plans and Pricing See Plans and Pricing
Hospira GENTAMICIN SULFATE gentamicin sulfate INJECTABLE;INJECTION 062420-001 Aug 15, 1983 AP RX No No See Plans and Pricing See Plans and Pricing
Hospira ALFENTANIL alfentanil hydrochloride INJECTABLE;INJECTION 075221-001 Oct 28, 1999 AP RX No No See Plans and Pricing See Plans and Pricing
Hospira PROPOFOL propofol INJECTABLE;INJECTION 077908-001 Mar 17, 2006 AB RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Hospira

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hospira TRACRIUM PRESERVATIVE FREE atracurium besylate INJECTABLE;INJECTION 018831-001 Nov 23, 1983 4,179,507 See Plans and Pricing
Hospira BRETYLOL bretylium tosylate INJECTABLE;INJECTION 017954-001 Approved Prior to Jan 1, 1982 RE29618 See Plans and Pricing
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-002 Mar 13, 2013 4,910,214*PED See Plans and Pricing
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-002 Mar 13, 2013 6,716,867*PED See Plans and Pricing
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-001 Dec 17, 1999 5,344,840 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for HOSPIRA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 4 mcg/mL, 50 mL and 100 mL vials ➤ Subscribe 2013-12-26
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe Injection 100 mcg/mL ➤ Subscribe 2009-04-08
➤ Subscribe Injection 4 mcg/mL, 20 mL vials ➤ Subscribe 2015-09-30
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16

Supplementary Protection Certificates for Hospira Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2404919 C02404919/01 Switzerland See Plans and Pricing PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE (LUMACAFTOR); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65981 02.09.2016
1499331 SPC/GB13/034 United Kingdom See Plans and Pricing PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
0266730 SPC/GB97/005 United Kingdom See Plans and Pricing PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926
1853250 2014C/037 Belgium See Plans and Pricing PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230
2563920 CA 2019 00001 Denmark See Plans and Pricing PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
Mallinckrodt
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.